HCWB — HCW Biologics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1828673 ·
Last close
$0.78
Market Cap
$1.43M
52W High
$23.94
52W Low
$0.74
ADV30
119,066
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 135,568 -93,887 -3,151,876 -5,219,231 26,768,318 741,324 19,340,704
Mar 2026 6,543,001 6,531,930 3,250,122 3,472,480 27,342,213 1,228,879 21,579,779
Dec 2025 27,010 5,401 -2,947,409 719,232 24,520,013 1,952,464 21,755,244
Sep 2025 15,606 3,121 -3,276,624 -4,554,336 25,445,540 1,096,909 27,552,737

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,136,822
Investing CF
$0
Financing CF
$10,439,184
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-28.43
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-110,262,597
Inventory
—
Receivables
$18,451
ST Investments
—
EBIT TTM
$-4,643,915
Pretax Income TTM
$-5,251,669
Interest Exp TTM
$607,754
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,721,186
EBITDA
$-5,584,538
Free Cash Flow
$-11,661,168
Enterprise Value
$9,933,403
Total Cash
$741,324
Total Debt
$6,561,361
Shares Out
1,836,324
Trailing EPS
$-16.62
Book Value
$4.59
ROE
-151.4%
ROA
-13.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 54,232 -11,257,288 -7,959,709 24,520,013 21,755,244 2,764,769 -13,391,617
Dec 2024 2,566,792 -27,629,216 -30,023,814 30,236,578 37,006,750 -6,770,172 -14,227,428
Dec 2023 2,841,794 -25,717,160 -24,994,277 28,513,660 15,051,943 13,461,717 -22,514,121
Dec 2022 6,722,090 -15,078,778 -14,900,703 46,809,155 9,380,649 37,428,506 -10,386,110
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$6,721,186
NetIncome TTM
$-5,581,855
OpCashFlow TTM
—
Assets (Latest)
$26,768,318
Forward EPS
$-0.55

Peers — same industry

TickerNameMarket CapLastDaily %
CPMD CANNAPHARMARX, INC. $1.42M $0.00 —
GNPX Genprex, Inc. $1.37M $1.67 —
RNAZ Transcode Therapeutics, Inc. $1.49M $1.41 —
KAPA Kairos Pharma, LTD. $1.35M $0.40 —
AGNPF Grey Matters Health Inc. $1.30M $0.24 —

News headlines (Yahoo Finance, 1h cache)

HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
2026-11-16 13:15 · Yahoo
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
2026-11-06 16:00 · Yahoo
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid
2026-11-06 14:15 · Yahoo
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
2026-11-05 13:45 · Yahoo
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
2026-10-09 13:00 · Yahoo
HCW Biologics Announces Pricing of $1.5 Million Private Placement
2026-09-24 12:25 · Yahoo
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent
2026-09-08 13:49 · Yahoo
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
2026-09-08 12:50 · Yahoo
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
2026-09-02 13:00 · Yahoo
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
2026-08-25 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.